IL‑6 plays a crucial role in epithelial‑mesenchymal transition and pro‑metastasis induced by sorafenib in liver cancer

• DOI: 10.3892/or.2021.7926
• Publication Date: 2021-01-07T09:21:51Z
• Authors: Ke‑Wei Zhang; Dong Wang; Hao Cai; Man‑Qing Cao; Yuan‑Yuan Zhang; Peng‑Yuan Zhuang; Jun Shen
• Keywords: Liver Cancer

Interleukin‑6 (IL‑6) is involved in various biological responses, including tumor progression, metastasis and chemoresistance. However, the role molecular mechanism of IL‑6 treatment sorafenib liver cancer remain unclear. In present study, through western blot analysis, Transwell assay, flow cytometric ELISA analysis immunohistochemistry it was revealed that promoted induced epithelial‑mesenchymal transition (EMT) cells vitro vivo, significantly increased expression. Endogenous or exogenous affected EMT progression Janus kinase 2/signal transducer activator transcription 3 (STAT3) signaling. Knocked out markedly attenuated pro‑metastasis effect susceptibility to it. conclusion, results indicated IL‑6/STAT3 signaling may be a novel therapeutic strategy for cancer.